Place of Origin: | CHINA |
---|---|
Brand Name: | TINGYI |
Certification: | GMP , ISO 9001:2008 |
Model Number: | CAS: 50-02-2 |
Minimum Order Quantity: | 10g |
Price: | Contact Us |
Packaging Details: | Stealth And Discreet Packaging |
Delivery Time: | Within 7 Working Days |
Payment Terms: | Bank Transfer - Bitcoin - Western Union - MoneyGram |
Supply Ability: | 2500 KG/Month |
Product Name: | Dexamethasone | MF: | C22H29FO5 |
---|---|---|---|
MW: | 392.46 | EINECS: | 200-003-9 |
MP: | 262-264 °C | Appearance: | White Solid |
High Light: | pharmaceutical active ingredients,pharmaceutical anabolic steroids |
Dexamethasone & Dexamethasone-17-acetate & Dexamethasone Palmitate
Basic Details:
Product Name: Dexamethasone
Synonyms: Acidocont; Deronil; Dexacortal; dexametona; Flumeprednisolon
CAS: 50-02-2
MF: C22H29FO5
MW: 392.46
EINECS: 200-003-9
mp: 262-264 °C(lit.)
alpha: 75 °(c=1, dioxane)
refractive index: 76 ° (C=1, Dioxane)
storage temp: 2-8°C
solubility ethanol: 1 mg/mL
appearance: white solid
Water Solubility: 10 mg/100 mL (25°C)
Stability: Stable. Combustible. Incompatible with strong oxidizing agents, strong bases, acid
anhydrides, acid chlorides. May be light sensitive
Application:
It is usually given by the inhaled route for direct effect on bronchial smooth muscle.This is usually
achieved through a metered dose inhaler (MDI), nebulizer or other proprietary delivery devices
(e.G.Rotahaler or Autohaler).In these forms of delivery, the maximal effect of salbutamol can take
place within five to 20 minutes of dosing, though some relief is immediately seen.It can also be
given intravenously.
Used in the treatment of bronchial asthma, asthmatic bronchitis, emphysema, patients
bronchospasm.
Dexamethasone-17-acetate
Basic Details:
Product Name: Dexamethasone-17-acetate
Synonyms: Dexamethason Acetate
CAS: 1177-87-3
MF: C24H31FO6
MW: 434.5
EINECS: 214-646-8
mp: 238-240 °C(lit.)
refractive index: 87 °(C=1, Dioxane)
storage temp: 2-8°C
appearance: Off-White Solid
Application:
Dexamethasone-17-acetate, a corticosteroid, is similar to a natural hormone produced by your
adrenal glands. It often is used to replace this chemical when your body does not make enough of
it. It relieves inflammation (swelling, heat, redness, and pain) and is used to treat certain forms of
arthritis; skin, blood, kidney, eye, thyroid, and intestinal disorders; severe allergies; and asthma.
Dexamethasone-17-acetate is also used to treat certain types of cancer.
Dexamethasone-17-acetate comes as a tablet and a solution to take by mouth. Your doctor will
prescribe a dosing schedule that is best for you. Follow the directions on your prescription label
carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take
Dexamethasone-17-acetate exactly as directed. Do not take more or less of it or take it more
often than prescribed by your doctor.
Special Note:
Do not stop taking Dexamethasone-17-acetate without talking to your doctor. Stopping the drug
abruptly can cause loss of appetite, upset stomach, vomiting, drowsiness, confusion, headache,
fever, joint and muscle pain, peeling skin, and weight loss. If you take large doses for a long time,
your doctor probably will decrease your dose gradually to allow your body to adjust before
stopping the drug completely. Watch for these side effects if you are gradually decreasing your
dose and after you stop taking the tablets or oral liquid, even if you switch to an inhalation
corticosteroid medication. If these problems occur, call your doctor immediately. You may need to
increase your dose of tablets or liquid temporarily or start taking them again.
Dexamethasone Palmitate
Basic Details:
Product Name: Dexamethasone palmitate
Synonyms: DXP;Limethason;Lipotalon
CAS: 14899-36-6
MF: C38H59FO6
MW: 630.87
mp: 60-65 °C
density: 1.12
storage temp: Hygroscopic, -20°C Freezer, Under Inert Atmosphere
appearance: Colourless Thick Oil
Description:
Dexamethasone palmitate (DXP) is a lipophilic prodrug of dexamethasone (DXM), a potent
corticosteroide used to treat a variety of ophthalmic diseases. The aim of the study was to
characterize the sustained release capacity (in rabbit), efficacy (in rat and rabbit), and safety (in
rabbit, cat, and minipig) of intravitreal (IVT) DXP emulsions in preclinical models.
Application:
Oil-in-water emulsions of DXP were administered by IVT injections in rats, rabbits, cats, or
minipigs. Efficacy was assessed in rabbits by the inhibition of VEGF-induced vascular leakage
and in rats by inhibition of laser-induced choroidal neovascularization. Concentrations of DXP
and DXM in aqueous humor, vitreous, retina, choroid, and blood were determined to characterize
the ocular and systemic pharmacokinetic (PK) profile. Complete ophthalmic examinations
(indirect ophthalmoscopy, slit-lamp biomacroscopy, electroretinography, tonometry) were
performed to assess the ocular safety of IVT DXP doses up to 2,600 μg in minipig, followed by
histopathologic examinations. A validated feline model of DXM-induced elevated intraocular
pressure (IOP) was used to assess the ocular hypertensive impact (i.e., the safety) of an IVT
injection of DXP emulsion.
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|